TCIM
SYRE icon

TIAA CREF Investment Management’s Spyre Therapeutics SYRE Stock Holding History

TIAA CREF Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$152K Hold
754
– – ﹤0.01% 2919
2018
Q4 		$141K Hold
754
– – ﹤0.01% 2925
2018
Q3 		$180K Sell
754
-246
-25% -$57.5K ﹤0.01% 3002
2018
Q2 		$265K Buy
+1,000
New +$246K ﹤0.01% 2982

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TIAA CREF Investment Management's SYRE Position: Q1 2019 in Review

TIAA CREF Investment Management held its Spyre Therapeutics (SYRE) position steady in Q1 2019 at 754 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #2919.

TIAA CREF Investment Management first reported a position in SYRE in Q2 2018 and has held it in 4 quarters since. The position peaked at $265K in Q2 2018. 71 funds tracked by Wall St. Rank hold SYRE as of Q1 2019.

  • TIAA CREF Investment Management held 754 shares of Spyre Therapeutics worth $152K as of Q1 2019.
  • TIAA CREF Investment Management left its Spyre Therapeutics share count unchanged in Q1 2019.
  • Spyre Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2919 holding.
  • TIAA CREF Investment Management first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's Spyre Therapeutics position peaked at $265K in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.